These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19636332)

  • 1. Impact of treating the metabolic syndrome on chronic kidney disease.
    Agrawal V; Shah A; Rice C; Franklin BA; McCullough PA
    Nat Rev Nephrol; 2009 Sep; 5(9):520-8. PubMed ID: 19636332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should the insulin resistance syndrome be treated in the elderly?
    Grant RW; Meigs JB
    Drugs Aging; 2004; 21(3):141-51. PubMed ID: 14979733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
    Després JP
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
    Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
    Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metabolic syndrome.
    Wagh A; Stone NJ
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):213-28. PubMed ID: 15151470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pioglitazone effects on blood pressure in patients with metabolic syndrome].
    Takahashi A; Kushiro T
    Nihon Rinsho; 2008 Aug; 66(8):1591-5. PubMed ID: 18700562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
    Orchard TJ; Temprosa M; Goldberg R; Haffner S; Ratner R; Marcovina S; Fowler S;
    Ann Intern Med; 2005 Apr; 142(8):611-9. PubMed ID: 15838067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metabolic syndrome].
    Boursier V
    J Mal Vasc; 2006 Sep; 31(4 Pt 1):190-201. PubMed ID: 17088787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome.
    Giles TD; Sander GE
    J Clin Hypertens (Greenwich); 2005 Nov; 7(11):669-78. PubMed ID: 16278525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome.
    Bourebaba Y; Mularczyk M; Marycz K; Bourebaba L
    Biomed Pharmacother; 2021 Feb; 134():111113. PubMed ID: 33341043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
    Namikoshi T; Tomita N; Satoh M; Haruna Y; Kobayashi S; Komai N; Sasaki T; Kashihara N
    Hypertens Res; 2008 Apr; 31(4):745-55. PubMed ID: 18633187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-reported sleep quality is associated with the metabolic syndrome.
    Jennings JR; Muldoon MF; Hall M; Buysse DJ; Manuck SB
    Sleep; 2007 Feb; 30(2):219-23. PubMed ID: 17326548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hypertension in children and adolescents with the metabolic syndrome.
    Puri M; Flynn JT
    J Cardiometab Syndr; 2006; 1(4):259-68. PubMed ID: 17679805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing the insulin resistance syndrome: a role for the thiazolidinediones.
    Zimmet P
    Trends Cardiovasc Med; 2002 Nov; 12(8):354-62. PubMed ID: 12536122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic options for metabolic syndrome in obese patients].
    Carella AM; Conte M
    Clin Ter; 2007; 158(5):457-64. PubMed ID: 18062354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
    Basile J; Houston M; Ferrario CM
    J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome.
    Gouni-Berthold I; Berthold HK
    Curr Pharm Des; 2014; 20(31):5025-38. PubMed ID: 24320031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
    Gupta AK; Smith SR; Greenway FL; Bray GA
    Diabetes Obes Metab; 2009 Apr; 11(4):330-7. PubMed ID: 19267711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
    Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
    J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.